ERBB2 and breast cancer: Previous studies have identified the subgroups of patients with triple-negative and human epidermal growth factor receptor 2 (HER2)-positive breast cancer as having an increased risk for the development of brain metastases [6–9], with up to half of patients with HER2-positive metastatic breast cancer experiencing brain metastases over time [10].